118.64
price down icon1.08%   -1.30
after-market Handel nachbörslich: 118.64
loading
Schlusskurs vom Vortag:
$119.94
Offen:
$119.81
24-Stunden-Volumen:
393.56K
Relative Volume:
0.69
Marktkapitalisierung:
$5.92B
Einnahmen:
$338.46M
Nettoeinkommen (Verlust:
$-310.96M
KGV:
-18.17
EPS:
-6.53
Netto-Cashflow:
$-132.82M
1W Leistung:
-2.31%
1M Leistung:
-5.22%
6M Leistung:
+20.45%
1J Leistung:
+40.97%
1-Tages-Spanne:
Value
$117.50
$120.78
1-Wochen-Bereich:
Value
$117.50
$124.53
52-Wochen-Spanne:
Value
$75.56
$139.13

Axsome Therapeutics Inc Stock (AXSM) Company Profile

Name
Firmenname
Axsome Therapeutics Inc
Name
Telefon
(212) 332-3241
Name
Adresse
ONE WORLD TRADE CENTER, 29TH FLOOR, NEW YORK
Name
Mitarbeiter
589
Name
Twitter
Name
Nächster Verdiensttermin
2025-02-18
Name
Neueste SEC-Einreichungen
Name
AXSM's Discussions on Twitter

Vergleichen Sie AXSM mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
AXSM
Axsome Therapeutics Inc
118.64 5.99B 338.46M -310.96M -132.82M -6.53
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
410.28 103.30B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
583.24 62.05B 14.21B 4.46B 3.56B 39.69
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
459.58 59.25B 2.46B -319.09M -52.09M -2.4669
Biotechnology icon
ARGX
Argen X Se Adr
797.35 48.22B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
ONC
Beone Medicines Ltd Adr
341.62 37.84B 4.56B -176.77M 225.30M -1.7177

Axsome Therapeutics Inc Stock (AXSM) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-10-01 Eingeleitet B. Riley Securities Buy
2025-09-03 Fortgesetzt Wells Fargo Overweight
2025-07-03 Fortgesetzt Morgan Stanley Overweight
2025-06-03 Eingeleitet Oppenheimer Outperform
2025-04-07 Eingeleitet Jefferies Buy
2025-02-11 Eingeleitet Deutsche Bank Buy
2024-12-31 Bestätigt Mizuho Outperform
2024-09-03 Eingeleitet Wells Fargo Overweight
2024-08-06 Hochstufung BofA Securities Neutral → Buy
2024-07-22 Eingeleitet Needham Buy
2024-04-29 Hochstufung Morgan Stanley Equal-Weight → Overweight
2024-03-19 Eingeleitet Robert W. Baird Outperform
2024-02-06 Eingeleitet UBS Buy
2024-01-25 Eingeleitet RBC Capital Mkts Outperform
2023-12-13 Eingeleitet Citigroup Buy
2023-08-08 Hochstufung BofA Securities Underperform → Neutral
2023-01-05 Eingeleitet Piper Sandler Neutral
2022-11-01 Eingeleitet Loop Capital Buy
2022-09-07 Fortgesetzt Mizuho Buy
2021-08-10 Herabstufung Morgan Stanley Overweight → Equal-Weight
2021-06-10 Eingeleitet Berenberg Buy
2021-01-08 Eingeleitet Jefferies Buy
2020-12-16 Eingeleitet Mizuho Buy
2020-09-29 Eingeleitet BofA Securities Underperform
2020-09-10 Eingeleitet Morgan Stanley Overweight
2020-04-28 Bestätigt H.C. Wainwright Buy
2020-04-14 Eingeleitet Cowen Outperform
2019-12-30 Bestätigt H.C. Wainwright Buy
2019-12-17 Bestätigt H.C. Wainwright Buy
2019-12-16 Bestätigt Guggenheim Buy
2019-10-16 Eingeleitet Guggenheim Buy
2019-09-18 Eingeleitet William Blair Outperform
2019-05-28 Eingeleitet SunTrust Buy
2019-05-23 Bestätigt H.C. Wainwright Buy
2019-04-08 Eingeleitet SVB Leerink Outperform
2019-03-15 Bestätigt H.C. Wainwright Buy
2016-10-03 Fortgesetzt Brean Capital Buy
2015-12-15 Eingeleitet Cantor Fitzgerald Buy
2015-12-14 Eingeleitet Ladenburg Thalmann Buy
Alle ansehen

Axsome Therapeutics Inc Aktie (AXSM) Neueste Nachrichten

pulisher
07:14 AM

Axsome Therapeutics Schedule Third Quarter 2025 Financial Results Announcement and Conference Call - Quiver Quantitative

07:14 AM
pulisher
07:10 AM

Axsome Therapeutics to Report Third Quarter 2025 Financial Results on November 3 - The Manila Times

07:10 AM
pulisher
07:00 AM

Q3 2025 Results Nov 3: Axsome Therapeutics to Report Results and Host 8:00 AM ET Conference Call; Webcast - Stock Titan

07:00 AM
pulisher
Oct 06, 2025

Is Axsome Therapeutics Inc 19X a good long term investmentVolatility Adjusted Trading & Free Trading Psychology Sessions - earlytimes.in

Oct 06, 2025
pulisher
Oct 06, 2025

Can Axsome Therapeutics Inc. stock withstand economic slowdownWeekly Trade Analysis & Verified Momentum Stock Alerts - newser.com

Oct 06, 2025
pulisher
Oct 05, 2025

Will Axsome Therapeutics Inc. (19X) stock outperform global peersM&A Rumor & High Conviction Trade Alerts - newser.com

Oct 05, 2025
pulisher
Oct 04, 2025

J. Safra Sarasin Holding AG Purchases 9,998 Shares of Axsome Therapeutics, Inc. $AXSM - MarketBeat

Oct 04, 2025
pulisher
Oct 03, 2025

Meet Herriot Tabuteau, The Haitian-Born Doctor Whose Brain Disorder Medications Turned Into A $6 Billion Empire - Black Enterprise

Oct 03, 2025
pulisher
Oct 03, 2025

What is B. Riley's Estimate for AXSM Q3 Earnings? - MarketBeat

Oct 03, 2025
pulisher
Oct 03, 2025

Real time social sentiment graph for Axsome Therapeutics Inc.Take Profit & Weekly Breakout Stock Alerts - newser.com

Oct 03, 2025
pulisher
Oct 02, 2025

Piper Sandler Maintains Overweight on Axsome (AXSM), Sees Growth in AD-Agitation - Yahoo Finance

Oct 02, 2025
pulisher
Oct 02, 2025

Migraine Market Growth to Surge During Forecast Period (2024–2034), Says DelveInsight | Eli Lilly and Company, Teva Pharmaceuticals, Axsome Therapeutics, AEON Biopharma, Inc., Charleston Laboratories - Barchart.com

Oct 02, 2025
pulisher
Oct 02, 2025

Axsome Therapeutics (NASDAQ:AXSM) Upgraded by B. Riley to Strong-Buy Rating - MarketBeat

Oct 02, 2025
pulisher
Oct 01, 2025

B. Riley Securities Initiates Coverage of Axsome Therapeutics (AXSM) with Buy Recommendation - Nasdaq

Oct 01, 2025
pulisher
Oct 01, 2025

AXSM: New 'Buy' Rating from B. Riley Securities with $179 PT | A - GuruFocus

Oct 01, 2025
pulisher
Oct 01, 2025

How Axsome Therapeutics Inc. (19X) stock trades after rate cuts2025 Support & Resistance & Intraday High Probability Setup Alerts - newser.com

Oct 01, 2025
pulisher
Oct 01, 2025

B. Riley Securities Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $179 - 富途牛牛

Oct 01, 2025
pulisher
Oct 01, 2025

Will Axsome Therapeutics Inc. (19X) stock deliver stable dividendsJuly 2025 Chart Watch & Risk Controlled Daily Trade Plans - newser.com

Oct 01, 2025
pulisher
Sep 30, 2025

Axsome Therapeutics Stock Slips On Q4 Profit Miss, But Retail Takes It In Stride - MSN

Sep 30, 2025
pulisher
Sep 30, 2025

H.C. Wainwright maintains Axsome stock Buy rating, $190 target - MSN

Sep 30, 2025
pulisher
Sep 30, 2025

14 Best Biotech Stocks to Buy Right Now - Insider Monkey

Sep 30, 2025
pulisher
Sep 30, 2025

Can Auvelity Drive Axsome's Growth Through the Rest of 2025? - The Globe and Mail

Sep 30, 2025
pulisher
Sep 30, 2025

Obstructive Sleep Apnea Market Insights Highlight Expanding Outlook Till 2034, DelveInsight Evaluates | Apnimed, Eli Lilly and Company, Axsome Therapeutics/Jazz Pharmaceuticals, Bioprojet Pharma - Barchart.com

Sep 30, 2025
pulisher
Sep 30, 2025

Obstructive Sleep Apnea Market Insights Highlight Expanding - openPR.com

Sep 30, 2025
pulisher
Sep 30, 2025

Prediction: These 2 Under-the-Radar Stocks Could Beat the Market in the Next 5 Years - Mitrade

Sep 30, 2025
pulisher
Sep 29, 2025

Axsome Sues Apotex to Block Copies of Symbravo Migraine Drug - Bloomberg Law News

Sep 29, 2025
pulisher
Sep 24, 2025

Axsome Therapeutics ($AXSM) Is Paying a $7.75M Settlement to Investors — Here’s How to Get Your Shar - TradingView

Sep 24, 2025
pulisher
Sep 23, 2025

Piper Sandler Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $148 - 富途牛牛

Sep 23, 2025
pulisher
Sep 23, 2025

Axsome Settles Investors' Drug Approval Suit For $7.8M - Law360

Sep 23, 2025
pulisher
Sep 23, 2025

Axsome Therapeutics ($AXSM) $7.75M Investor Settlement - TradingView

Sep 23, 2025
pulisher
Sep 23, 2025

Axsome Therapeutics and $AXSM Investors Finalise $7.75M Settlement Agreement - TradingView

Sep 23, 2025
pulisher
Sep 23, 2025

Cantor Fitzgerald Has Weak Forecast for AXSM FY2026 Earnings - MarketBeat

Sep 23, 2025
pulisher
Sep 23, 2025

Assenagon Asset Management S.A. Cuts Stake in Axsome Therapeutics, Inc. $AXSM - MarketBeat

Sep 23, 2025
pulisher
Sep 23, 2025

Axsome therapeutics COO Jacobson sells $1.15 million in shares By Investing.com - Investing.com Canada

Sep 23, 2025
pulisher
Sep 22, 2025

Axsome therapeutics COO Jacobson sells $1.15 million in shares - Investing.com

Sep 22, 2025
pulisher
Sep 22, 2025

Axsome Therapeutics (NASDAQ:AXSM) COO Mark L. Jacobson Sells 10,000 Shares - MarketBeat

Sep 22, 2025
pulisher
Sep 22, 2025

Axsome to Settle Class Suit Over Migraine Drug for $7.75 Million - Bloomberg Law News

Sep 22, 2025
pulisher
Sep 22, 2025

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Given Average Rating of "Buy" by Analysts - MarketBeat

Sep 22, 2025
pulisher
Sep 21, 2025

Axsome Therapeutics (NASDAQ:AXSM) COO Sells $5,241,237.84 in Stock - MarketBeat

Sep 21, 2025
pulisher
Sep 21, 2025

Pallas Capital Advisors LLC Purchases 2,492 Shares of Axsome Therapeutics, Inc. $AXSM - MarketBeat

Sep 21, 2025
pulisher
Sep 21, 2025

10,400 Shares in Axsome Therapeutics, Inc. $AXSM Acquired by Strs Ohio - MarketBeat

Sep 21, 2025
pulisher
Sep 21, 2025

Herriot Tabuteau Sells 15,254 Shares of Axsome Therapeutics (NASDAQ:AXSM) Stock - MarketBeat

Sep 21, 2025
pulisher
Sep 21, 2025

Herriot Tabuteau Sells 27,907 Shares of Axsome Therapeutics (NASDAQ:AXSM) Stock - MarketBeat

Sep 21, 2025
pulisher
Sep 21, 2025

Herriot Tabuteau Sells 19,719 Shares of Axsome Therapeutics (NASDAQ:AXSM) Stock - MarketBeat

Sep 21, 2025
pulisher
Sep 20, 2025

Market Moves: Can Axsome Therapeutics Inc. continue delivering strong returnsTrade Risk Assessment & Stepwise Swing Trade Plans - khodrobank.com

Sep 20, 2025
pulisher
Sep 20, 2025

Intech Investment Management LLC Boosts Position in Axsome Therapeutics, Inc. $AXSM - MarketBeat

Sep 20, 2025
pulisher
Sep 20, 2025

How Investors May Respond To Axsome Therapeutics (AXSM) Showcasing Late-Stage CNS Pipeline Data at Psych Congress - Yahoo Finance

Sep 20, 2025

Finanzdaten der Axsome Therapeutics Inc-Aktie (AXSM)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$22.29
price up icon 0.63%
$87.17
price down icon 0.07%
$32.64
price down icon 2.01%
$106.06
price up icon 0.86%
$162.32
price up icon 2.55%
biotechnology ONC
$341.62
price down icon 0.84%
Kapitalisierung:     |  Volumen (24h):